WuXi Biologics (2269 HK) - The Strength and the Potential Risk
This article analyzed WuXi Biologics in terms of its performance in 2020, the projects, production capacity, competition pattern, key catalyst and...
752 Views
Pharmaron Beijing IPO: H-Share Valuation Enticing
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
762 Views